Shivom is a global blockchain-genomics ecosystem powering the next era of precision medicine. Shivom is building a genomic and health data hub by combining blockchain, genomic DNA sequencing, artificial intelligence and cryptography to power secure and personalized medicine.

Shivom works on principles of collaboration and integrity, allowing users to own, manage and monetize their genomics and health data. The Shivom team aims to reach even underserved and low-income countries where such services have not been previously available. This solution will create shared value for individuals, not-for-profit organizations, governments, and for-profit entities alike.

Team:

• Dr. Axel Schumacher: Co-Founder & CEO.
• Gourish Singla: Co-Founder & COO.
• Sally Eaves: Co-Founder & CMO.
• Per Lind: Co-Founder & CSO.
• Henry Ines: Chief Innovation Officer.
• Akash Gaurav: Co-Founder & CTO.

Shivom will be holding its ICO on the 16th of April, 2018. The ICO token supply represents 33% of the total token supply, so there will be a total of 990,000,000 tokens available, for 0.00014 ETH each during the offering. The ICO funding target is 15,000 ETH, the funding cap is 75,000 ETH and is expected to end on the 16th of May, 2018 or when the funding cap is reached. Any unsold/remaining tokens will be burned.

Token Reserve Split (67%):

• 20% Pool;
• 20% Reserve;
• 14% Founders;
• 10% Advisors;
• 3% Community;

Shivom ICO will feature a bonus program and a bounty campaign, and the token will not be mineable.